Hepatectomy After Conversion Therapy for Initially Unresectable HCC: What is the Difference?

被引:24
作者
Luo, Laihui [1 ]
He, Yongzhu [1 ]
Zhu, Guoqing [1 ]
Xiao, Yongqiang [1 ]
Song, Shengjiang [1 ]
Ge, Xian [2 ]
Wang, Tao [3 ]
Xie, Jin [1 ]
Deng, Wei [1 ]
Hu, Zhigao [1 ]
Shan, Renfeng [1 ,4 ]
机构
[1] First Affiliated Hosp Nanchang, Dept Gen Surg, Nanchang, Peoples R China
[2] First Affiliated Hosp Nanchang, Dept Pathol, Nanchang, Peoples R China
[3] First Affiliated Hosp Nanchang, Dept Day Surg Ward, Nanchang, Peoples R China
[4] Nanchang Univ, Affiliated Hosp 1, Dept Gen Surg, 17 Yong Wai Zheng St, Nanchang 330006, Peoples R China
关键词
hepatocellular carcinoma; conversion therapy; hepatectomy; post-hepatectomy liver failure; pathological complete response; HEPATOCELLULAR-CARCINOMA; TRANSARTERIAL CHEMOEMBOLIZATION; CHEMOTHERAPY; OXALIPLATIN; MANAGEMENT; OUTCOMES;
D O I
10.2147/JHC.S388965
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Conversion therapy gives some patients with initially unresectable hepatocellular carcinoma (HCC) access to surgery. The purpose of this study was to evaluate the safety and efficacy of hepatectomy after conversion therapy and how it differed from those who undergoing direct hepatectomy.Patients and Methods: From January 2018 to April 2022, 745 patients underwent hepatectomy for HCC were enrolled. Among them, 41 patients of unresectable HCC underwent hepatectomy after conversion therapy. A demographically and clinically comparable cohort was created from the remaining patients in a 1:1 ratio using propensity score matching.Results: The median duration of conversion therapy was 108 (42-298) days, 8 patients achieved complete response (CR) and 33 achieved partial response (PR). Conversion therapy resulted in some degree of myelosuppression, but liver function index remained good. Compared with the direct hepatectomy group, the conversion group had more blood loss (600 mL vs 400 mL,p=0.015), longer operative time (270 min vs 240 min, p=0.02), higher blood transfusion rates, and longer hospital stay (8 days vs 11 days,p<0.001). Patients in the conversion group had significantly more complications of any grade (82.9% vs 51.2%, p=0.002) and grade 3/4 (26.8% vs 4.9%, p=0.013), and 6 patients developed post-hepatectomy liver failure (PHLF). There were no deaths in either group. All patients achieved R0 resection, 6 (6/41, 14.6%) achieved pathological complete response (pCR), 14 achieved major pathologic responses (MPR). During a median follow-up of 12.8 months, 14 patients in the conversion group experienced recurrence or metastasis, no deaths.Conclusion: Hepatectomy after conversion therapy was more difficult than direct hepatectomy, but accurate preoperative assessment could ensure the safety of the surgery. The damage of liver function after conversion therapy was more severe than expected, PHLF should be prevented and treated. Hepatectomy was effective and necessary, postoperative pathological examination could provide guidance for adjuvant therapy.
引用
收藏
页码:1353 / 1368
页数:16
相关论文
共 37 条
[1]   Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases [J].
Aloia, Thomas ;
Sebagh, Mylene ;
Plasse, Marylene ;
Karam, Vincent ;
Levi, Francis ;
Giacchetti, Sylvie ;
Azoulay, Daniel ;
Bismuth, Henri ;
Castaing, Denis ;
Adam, Rene .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (31) :4983-4990
[2]   Sorafenib treatment has the potential to downstage advanced hepatocellular carcinoma before liver resection [J].
Bertacco, Alessandra ;
Vitale, Alessandro ;
Mescoli, Claudia ;
Cillo, Umberto .
PERSONALIZED MEDICINE, 2020, 17 (02) :83-87
[3]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[4]   Liver regeneration and inflammation: from fundamental science to clinical applications [J].
Campana, Lara ;
Esser, Hannah ;
Huch, Meritxell ;
Forbes, Stuart .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2021, 22 (09) :608-624
[5]   Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study [J].
Chen, Song ;
Wu, Zhiqiang ;
Shi, Feng ;
Mai, Qicong ;
Wang, Liguang ;
Wang, Fan ;
Zhuang, Wenquan ;
Chen, Xiaoming ;
Chen, Huanwei ;
Xu, Bo ;
Lai, Jiaming ;
Guo, Wenbo .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (08) :2115-2125
[6]   The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma [J].
D'Avola, Delia ;
Granito, Alessandro ;
De La Torre-Alaez, Manuel ;
Piscaglia, Fabio .
JOURNAL OF HEPATOLOGY, 2022, 76 (05) :1185-1198
[7]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
[8]   Consensus recommendations of three-dimensional visualization for diagnosis and management of liver diseases [J].
Fang, Chihua ;
An, Jihyun ;
Bruno, Antonio ;
Cai, Xiujun ;
Fan, Jia ;
Fujimoto, Jiro ;
Golfieri, Rita ;
Hao, Xishan ;
Jiang, Hongchi ;
Jiao, Long R. ;
Kulkarni, Anand V. ;
Lang, Hauke ;
Lesmana, Cosmas Rinaldi A. ;
Li, Qiang ;
Liu, Lianxin ;
Liu, Yingbin ;
Lau, Wanyee ;
Lu, Qiping ;
Man, Kwan ;
Maruyama, Hitoshi ;
Mosconi, Cristina ;
Ormeci, Necati ;
Pavlides, Michael ;
Rezende, Guilherme ;
Sohn, Joo Hyun ;
Treeprasertsuk, Sombat ;
Vilgrain, Valerie ;
Wen, Hao ;
Wen, Sai ;
Quan, Xianyao ;
Ximenes, Rafael ;
Yang, Yinmo ;
Zhang, Bixiang ;
Zhang, Weiqi ;
Zhang, Peng ;
Zhang, Shaoxiang ;
Qi, Xiaolong .
HEPATOLOGY INTERNATIONAL, 2020, 14 (04) :437-453
[9]   Liver Resection Promotes (Regulates) Proinflammatory Cytokines in Patients with Hepatocellular Carcinoma [J].
Fathi, Farshid ;
Sanei, Behnam ;
Ganjalikhani Hakemi, Mazdak ;
Saidi, Reza F. ;
Rezaei, Abbas .
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 2021
[10]   Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma [J].
Finn, Richard S. ;
Ikeda, Masafumi ;
Zhu, Andrew X. ;
Sung, Max W. ;
Baron, Ari D. ;
Kudo, Masatoshi ;
Okusaka, Takuji ;
Kobayashi, Masahiro ;
Kumada, Hiromitsu ;
Kaneko, Shuichi ;
Pracht, Marc ;
Mamontov, Konstantin ;
Meyer, Tim ;
Kubota, Tomoki ;
Dutcus, Corina E. ;
Saito, Kenichi ;
Siegel, Abby B. ;
Dubrovsky, Leonid ;
Mody, Kalgi ;
Llovet, Josep M. .
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (26) :2960-+